Tricyanoaminopropene

Last updated
Tricyanoaminopropene
Tricyanoaminopropene.png
Clinical data
Trade names Triap
Legal status
Legal status
  • Investigational
Identifiers
  • 1,1,3-tricyano-2-amino-1-propene
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard 100.011.616 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C6H4N4
Molar mass 132.126 g·mol−1
3D model (JSmol)
  • C(C#N)C(=C(C#N)C#N)N
  • InChI=1S/C6H4N4/c7-2-1-6(10)5(3-8)4-9/h1,10H2
  • Key:BNHGNFYPZNDLAF-UHFFFAOYSA-N
   (verify)

Tricyanoaminopropene (TRIAP, TCAP, Malononitrile Dimer, 1,1,3-tricyano-2-amino-1-propene) is a nootropic drug which mimics the function of nerve growth factor and increases the growth of nerves and tissue regeneration both in isolated tissues [1] and in vivo. It stimulates the action of the enzyme choline acetyltransferase, resulting in increased acetylcholine production. [2] This then results in increased synthesis of RNA in many different tissues in the body. [3] However it also suppresses the production of thyroxine, causing temporary hypothyroidism which returns to normal once the drug is discontinued. [4]

Tricyanoaminopropene reduces the amnesia produced by electroconvulsive shock, [5] and animal tests suggested nootropic activity, [6] [7] [8] but no beneficial effect was found when it was tested in mentally disabled children, [9] and administration to pregnant rats actually reduced learning ability in their young because of its anti-thyroid hormone effects. [10] This drug thus produces two effects which oppose each other, with the nootropic effect from the increased acetylcholine production cancelled out by the opposite effect produced by the decrease in production of thyroxine. It is not known whether the efficacy of the drug could be improved by supplementation with additional thyroxine or equivalent drugs.

See also

Related Research Articles

<span class="mw-page-title-main">Acetylcholine</span> Organic chemical and neurotransmitter

Acetylcholine (ACh) is an organic chemical that functions in the brain and body of many types of animals as a neurotransmitter. Its name is derived from its chemical structure: it is an ester of acetic acid and choline. Parts in the body that use or are affected by acetylcholine are referred to as cholinergic. Substances that increase or decrease the overall activity of the cholinergic system are called cholinergics and anticholinergics, respectively.

<span class="mw-page-title-main">Transferase</span> Class of enzymes

A transferase is any one of a class of enzymes that catalyse the transfer of specific functional groups from one molecule to another. They are involved in hundreds of different biochemical pathways throughout biology, and are integral to some of life's most important processes.

<span class="mw-page-title-main">Choline acetyltransferase</span> Protein-coding gene in the species Homo sapiens

Choline acetyltransferase is a transferase enzyme responsible for the synthesis of the neurotransmitter acetylcholine. ChAT catalyzes the transfer of an acetyl group from the coenzyme acetyl-CoA to choline, yielding acetylcholine (ACh). ChAT is found in high concentration in cholinergic neurons, both in the central nervous system (CNS) and peripheral nervous system (PNS). As with most nerve terminal proteins, ChAT is produced in the body of the neuron and is transported to the nerve terminal, where its concentration is highest. Presence of ChAT in a nerve cell classifies this cell as a "cholinergic" neuron. In humans, the choline acetyltransferase enzyme is encoded by the CHAT gene.

<span class="mw-page-title-main">Nootropic</span> Drug, supplement, or other substance that improves cognitive function

Nootropics are a wide range of natural or synthetic supplements or drugs and other substances that are claimed to improve cognitive function or to promote relaxation, particularly boosting mood, executive functions, attention, memory, creativity, or motivation in healthy individuals. The most commonly used nootropic in the world is caffeine.

<span class="mw-page-title-main">Piracetam</span> Cerebral activators

Piracetam is a drug marketed as a treatment for myoclonus. It is also used as a cognitive enhancer to improve memory, attention, and learning. Evidence to support its use is unclear, with some studies showing modest benefits in specific populations and others showing minimal or no benefit. Piracetam is sold as a medication in many European countries. Sale of piracetam is not illegal in the United States, although it is not regulated nor approved by the FDA so it is legally sold for research use only.

<span class="mw-page-title-main">Oxiracetam</span> Chemical compound

Oxiracetam is a nootropic drug of the racetam family and a very mild stimulant. Several studies suggest that the substance is safe even when high doses are consumed for a long period of time. However, the mechanism of action of the racetam drug family is still a matter of research. Oxiracetam is not approved by Food and Drug Administration for any medical use in the United States.

<span class="mw-page-title-main">Transthyretin</span> Serim protein related to amyloid diseases

Transthyretin (TTR or TBPA) is a transport protein in the plasma and cerebrospinal fluid that transports the thyroid hormone thyroxine (T4) and retinol to the liver. This is how transthyretin gained its name: transports thyroxine and retinol. The liver secretes TTR into the blood, and the choroid plexus secretes TTR into the cerebrospinal fluid.

<span class="mw-page-title-main">Coluracetam</span>

Coluracetam is a purported nootropic agent of the racetam family. It is contains a chemical group that is a bioisostere of the 9-amino-tetrahydroacridine family. It was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California. Findings from phase IIa clinical trials have suggested that it would be a potential medication for comorbid MDD with generalized anxiety disorder (GAD). BrainCells Inc is currently out-licensing the drug for this purpose. It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury.

<span class="mw-page-title-main">Synaptosome</span>

A synaptosome is an isolated synaptic terminal from a neuron. Synaptosomes are obtained by mild homogenization of nervous tissue under isotonic conditions and subsequent fractionation using differential and density gradient centrifugation. Liquid shear detaches the nerve terminals from the axon and the plasma membrane surrounding the nerve terminal particle reseals. Synaptosomes are osmotically sensitive, contain numerous small clear synaptic vesicles, sometimes larger dense-core vesicles and frequently one or more small mitochondria. They carry the morphological features and most of the chemical properties of the original nerve terminal. Synaptosomes isolated from mammalian brain often retain a piece of the attached postsynaptic membrane, facing the active zone.

Racetams are a class of drugs that share a pyrrolidone nucleus. Some, such as piracetam, aniracetam, oxiracetam, pramiracetam and phenylpiracetam are considered nootropics. Others such as levetiracetam, brivaracetam, and seletracetam are anticonvulsants.

<span class="mw-page-title-main">NMDA receptor antagonist</span> Class of anesthetics

NMDA receptor antagonists are a class of drugs that work to antagonize, or inhibit the action of, the N-Methyl-D-aspartate receptor (NMDAR). They are commonly used as anesthetics for animals and humans; the state of anesthesia they induce is referred to as dissociative anesthesia.

<i>gamma</i>-Amino-<i>beta</i>-hydroxybutyric acid

γ-Amino-β-hydroxybutyric acid (GABOB), also known as β-hydroxy-γ-aminobutyric acid (β-hydroxy-GABA), and sold under the brand name Gamibetal among others, is an anticonvulsant which is used for the treatment of epilepsy in Europe, Japan, and Mexico. It is a GABA analogue, or an analogue of the neurotransmitter γ-aminobutyric acid (GABA), and has been found to be an endogenous metabolite of GABA.

<span class="mw-page-title-main">LY-503430</span> Chemical compound

LY-503430 is an AMPA receptor positive allosteric modulator developed by Eli Lilly.

<span class="mw-page-title-main">Neramexane</span> Chemical compound

Neramexane is a drug related to memantine, which acts as an NMDA antagonist and has neuroprotective effects. It is being developed for various possible applications, including treatment of tinnitus, Alzheimer's disease, drug addiction and as an analgesic. Animal studies have also suggested antidepressant and nootropic actions, so there are a wide range of potential applications this drug may be used for. It also acts as a nicotinic acetylcholine receptor antagonist.

<span class="mw-page-title-main">SB-271046</span> Chemical compound

SB-271046 is a drug which is used in scientific research. It was one of the first selective 5-HT6 receptor antagonists to be discovered, and was found through high-throughput screening of the SmithKline Beecham Compound Bank using cloned 5-HT6 receptors as a target, with an initial lead compound being developed into SB-271046 through a structure-activity relationship (SAR) study. SB-271046 was found to be potent and selective in vitro and had good oral bioavailability in vivo, but had poor penetration across the blood–brain barrier, so further SAR work was then conducted, which led to improved 5-HT6 antagonists such as SB-357,134 and SB-399,885.

<span class="mw-page-title-main">Bifemelane</span>

Bifemelane (INN), or bifemelane hydrochloride (JAN), also known as 4-(O-benzylphenoxy)-N-methylbutylamine, is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms in Japan, and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma. Bifemelane acts as a monoamine oxidase inhibitor (MAOI) of both isoenzymes, with competitive (reversible) inhibition of MAO-A and non-competitive (irreversible) inhibition of MAO-B, and also acts (weakly) as a norepinephrine reuptake inhibitor. The drug has nootropic, neuroprotective, and antidepressant-like effects in animal models, and appears to enhance the cholinergic system in the brain.

<span class="mw-page-title-main">Naphthylvinylpyridine</span> Chemical compound

Naphthylvinylpyridine (NVP) is a naphthalene derivative that possesses anticholinergic activity similar to that of atropine. However, NVP's method of acetylcholine (ACh) antagonism involves inhibiting the enzyme choline acetyltransferase.

<span class="mw-page-title-main">A-77636</span> Chemical compound

A-77636 is a synthetic drug which acts as a selective D1 receptor full agonist. It has nootropic, anorectic, rewarding and antiparkinsonian effects in animal studies, but its high potency and long duration of action causes D1 receptor downregulation and tachyphylaxis, and unlike other D1 full agonists such as SKF-82,958, it does not produce place preference in animals. A-77636 partially substituted for cocaine in animal studies, and has been suggested for use as a possible substitute drug in treating addiction, but it is better known for its use in studying the role of D1 receptors in the brain.

<span class="mw-page-title-main">Cholinergic neuron</span> Type of nerve cell

A cholinergic neuron is a nerve cell which mainly uses the neurotransmitter acetylcholine (ACh) to send its messages. Many neurological systems are cholinergic. Cholinergic neurons provide the primary source of acetylcholine to the cerebral cortex, and promote cortical activation during both wakefulness and rapid eye movement sleep. The cholinergic system of neurons has been a main focus of research in aging and neural degradation, specifically as it relates to Alzheimer's disease. The dysfunction and loss of basal forebrain cholinergic neurons and their cortical projections are among the earliest pathological events in Alzheimer's disease.

Fluciclovine (<sup>18</sup>F)

Fluciclovine (18F), also known as anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid, or as Axumin, is a diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels.

References

  1. Paul JW, Quach TT, Duchemin AM, Schrier BK, DaVanzo JP (August 1990). "1,1,3 tricyano-2-amino-1-propene (Triap): a small molecule which mimics or potentiates nerve growth factor". Brain Research. Developmental Brain Research. 55 (1): 21–27. doi:10.1016/0165-3806(90)90101-4. PMID   2208638.
  2. Paul JW, DaVanzo JP (June 1992). "1,1,3 Tricyano-2-amino-1-propene (Triap) stimulates choline acetyltransferase activity in vitro and in vivo". Brain Research. Developmental Brain Research. 67 (2): 113–120. doi:10.1016/0165-3806(92)90212-f. PMID   1511511.
  3. Dhindsa KS, Enesco HE (1978). "Radioautographic study of the effect of malononitrile dimer on RNA synthesis in mice". Acta Anatomica. 100 (1): 44–50. doi:10.1159/000144880. PMID   899675.
  4. Dhindsa KS (1980). "Histological changes in the thyroid gland of the mouse following treatment with 1, 1, 3-tricyano-2-amino-1-propene". Acta Anatomica. 106 (4): 468–472. doi:10.1159/000145216. PMID   7386168.
  5. Essman WB (1966). "Effect of tricyanoaminopropene on the amnesic effect of electroconvulsive shock". Psychopharmacologia. 9 (5): 426–433. doi:10.1007/BF00406452. PMID   4173302. S2CID   20265191.
  6. Rahwan RG (November 1971). "The biochemical and pharmacological basis of learning and memory". Agents and Actions. 2 (3): 87–102. doi:10.1007/bf01990087. PMID   4950562. S2CID   38569933.
  7. Banfi S, Cornelli U, Fonio W, Dorigotti L (December 1982). "A screening method for substances potentially active on learning and memory". Journal of Pharmacological Methods. 8 (4): 255–263. doi:10.1016/0160-5402(82)90042-0. PMID   7154677.
  8. Corson JA. "Studies of the Effects of Manipulation of Brain Metabolism on Learning. I. Vitamin B12. II. Magnesium Pemoline (Cylert). III. Malononitrile Dimer (u9189). IV. Anodal Polarization".[ dead link ]
  9. Panzer JD, Atkinson WH (1969). "Tricyanoaminopropene (TCAP): lace of improvement of mentation in mentally retarded children". Psychosomatics. 10 (2): 136–140. doi:10.1016/S0033-3182(69)71773-X. PMID   4181970.
  10. Davenport JW (February 1970). "Cretinism in rats: enduring behavioral deficit induced by tricyanoaminopropene". Science. 167 (3920): 1007–1008. Bibcode:1970Sci...167.1007D. doi:10.1126/science.167.3920.1007. PMID   4188980. S2CID   20247454.